[go: up one dir, main page]

NO20001200L - Pyrrolopyrrolonderivater som inhibitorer av nøyrofil elastase - Google Patents

Pyrrolopyrrolonderivater som inhibitorer av nøyrofil elastase

Info

Publication number
NO20001200L
NO20001200L NO20001200A NO20001200A NO20001200L NO 20001200 L NO20001200 L NO 20001200L NO 20001200 A NO20001200 A NO 20001200A NO 20001200 A NO20001200 A NO 20001200A NO 20001200 L NO20001200 L NO 20001200L
Authority
NO
Norway
Prior art keywords
inhibitors
neutrophil elastase
pyrrolopyrrolone
derivatives
pyrrolopyrrolone derivatives
Prior art date
Application number
NO20001200A
Other languages
English (en)
Other versions
NO20001200D0 (no
Inventor
Michael Dennis Dowle
Harry Finch
Lee Andrew Harrison
Graham George Adam Inglis
Martin Redpath Johnson
Simon John Fawcett Macdonald
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20001200D0 publication Critical patent/NO20001200D0/no
Publication of NO20001200L publication Critical patent/NO20001200L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det er beskrevet en forbindelser med formel (I) (I) (relative stereokjemi angitt) hvor R1, R2 og R3 er som definert i beskrivelsen. Forbindelser med formel (l) er nyttige bl.a. ved behandling av inflammatoriske sykdommer i luftveiene.
NO20001200A 1997-09-09 2000-03-08 Pyrrolopyrrolonderivater som inhibitorer av nøyrofil elastase NO20001200L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9719187.8A GB9719187D0 (en) 1997-09-09 1997-09-09 Compounds
PCT/EP1998/005604 WO1999012931A1 (en) 1997-09-09 1998-09-07 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase

Publications (2)

Publication Number Publication Date
NO20001200D0 NO20001200D0 (no) 2000-03-08
NO20001200L true NO20001200L (no) 2000-05-08

Family

ID=10818820

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001200A NO20001200L (no) 1997-09-09 2000-03-08 Pyrrolopyrrolonderivater som inhibitorer av nøyrofil elastase

Country Status (24)

Country Link
US (1) US6228853B1 (no)
EP (1) EP1019406A1 (no)
JP (1) JP2001515902A (no)
KR (1) KR20010023830A (no)
CN (1) CN1278821A (no)
AP (1) AP2000001760A0 (no)
AU (1) AU9536098A (no)
BR (1) BR9811651A (no)
CA (1) CA2303249A1 (no)
EA (1) EA200000205A1 (no)
EE (1) EE200000137A (no)
GB (1) GB9719187D0 (no)
HR (1) HRP20000136A2 (no)
HU (1) HUP0003475A3 (no)
ID (1) ID24364A (no)
IL (1) IL134935A0 (no)
IS (1) IS5394A (no)
MA (1) MA26544A1 (no)
NO (1) NO20001200L (no)
PL (1) PL339186A1 (no)
SK (1) SK3242000A3 (no)
TR (1) TR200001026T2 (no)
WO (1) WO1999012931A1 (no)
ZA (1) ZA988162B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
US7745226B2 (en) * 2005-04-06 2010-06-29 Quest Diagnostics Investments Incorporated Methods for detecting vitamin D metabolites
US7972868B2 (en) 2007-11-28 2011-07-05 Quest Diagnostics Investments Incorporated Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry
US7977117B2 (en) 2009-12-03 2011-07-12 Quest Diagnostics Investments Incorprated Vitamin D metabolite determination utilizing mass spectrometry following derivatization
US9034653B2 (en) 2009-12-11 2015-05-19 Quest Diagnostics Investments Inc. Mass spectrometry of steroidal compounds in multiplexed patient samples
JP6113504B2 (ja) 2009-12-11 2017-04-12 クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド 非誘導体化非代謝化ビタミンｄの質量分析法による決定
EP4031138A1 (en) 2019-09-17 2022-07-27 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
AU2021256835A1 (en) 2020-04-16 2022-10-13 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983245A (en) 1975-02-06 1976-09-28 Smithkline Corporation Certain 4-(3-azacycloalkoxy or azacycloalkylmethoxy)benzoylbenzofurans or benzothiophenes
GB8512230D0 (en) 1985-05-14 1985-06-19 Shell Internationale Researche Preparation of carboxylic acid salt
GB9211783D0 (en) 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9402680D0 (en) 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives
CZ212498A3 (cs) * 1996-01-03 1998-12-16 Smithkline Beecham P. L. C. Karbamoyloxyderiváty mutilinu, způsob výroby a farmaceutický prosředek
AR006401A1 (es) * 1996-03-28 1999-08-25 Glaxo Group Ltd Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.

Also Published As

Publication number Publication date
AU9536098A (en) 1999-03-29
US6228853B1 (en) 2001-05-08
MA26544A1 (fr) 2004-12-20
IL134935A0 (en) 2001-05-20
CN1278821A (zh) 2001-01-03
PL339186A1 (en) 2000-12-04
KR20010023830A (ko) 2001-03-26
HRP20000136A2 (en) 2000-08-31
WO1999012931A1 (en) 1999-03-18
ID24364A (id) 2000-07-13
SK3242000A3 (en) 2001-03-12
GB9719187D0 (en) 1997-11-12
EP1019406A1 (en) 2000-07-19
TR200001026T2 (tr) 2000-09-21
EA200000205A1 (ru) 2000-10-30
NO20001200D0 (no) 2000-03-08
ZA988162B (en) 2000-03-22
IS5394A (is) 2000-03-03
EE200000137A (et) 2001-02-15
CA2303249A1 (en) 1999-03-18
JP2001515902A (ja) 2001-09-25
HUP0003475A3 (en) 2002-01-28
HUP0003475A2 (hu) 2001-09-28
BR9811651A (pt) 2000-08-08
AP2000001760A0 (en) 2000-03-31

Similar Documents

Publication Publication Date Title
CA2216796A1 (en) Quinazoline derivatives
WO2004024081A3 (en) Acetyl 2-hydroxy-1,3 diaminoalkanes
DK0766670T3 (da) Tri-substituerede phenylderivater anvendelige som PDE IV inhibitorer
ATE306261T1 (de) Antithrombosemittel
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
IL133623A0 (en) Antithrombotic agents
CA2319005A1 (en) 2-pyridylmethylamine derivatives useful as fungicides
NO972481L (no) Fremgangsmåte ved fremstilling av sildenafil
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
NO996108L (no) 9-oksinerytromycinderivater
MY132473A (en) Crystalline hydrochloride of (r)-(-)-2-<n-[4-(1,1- dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl>-chroman
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2001003685A3 (en) Novel prodrugs for antimicrobial amidines
NO984470L (no) Pyrrolopyrrolon-derivater som inhibitorer for neutrofil elastase
SE9803518D0 (sv) Novel compounds
NO20001198L (no) Pyrrolopyrrolondervater som inhibitorer av nøytrofil elastase
NO20001200L (no) Pyrrolopyrrolonderivater som inhibitorer av nøyrofil elastase
CA2309474A1 (en) New 4-arylpiperidine derivatives for the treatment of pruritus
CA2192786A1 (en) Cyclopeptolide inhibitors of adhesion molecules
AU5390900A (en) Potassium channel blocking agents
NO994131L (no) Fremgangsmaate for fremstilling av benzotiazolonforbindelser
TNSN05067A1 (en) Acetyl 2-hydroxy- 1,3 diaminoalkanes
EP0784973A3 (en) Quinoxaline derivatives for treating tinnitus
SE9901901D0 (sv) Compounds
DK0832085T3 (da) Phosphinsyrederivater med metallopeptidaseinhiberende aktivitet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application